Literature DB >> 9311887

Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D.

W C Manning1, X Paliard, S Zhou, M Pat Bland, A Y Lee, K Hong, C M Walker, J A Escobedo, V Dwarki.   

Abstract

Intramuscular injection of mice with an adeno-associated virus (AAV) vector expressing herpes simplex virus type 2 glycoprotein B led to the generation of both gB-specific major histocompatibility complex class I-restricted cytotoxic T lymphocytes and anti-gB antibody. AAV-mediated immunization was more potent than plasmid DNA or protein in generating antibody responses.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9311887      PMCID： PMC192154          DOI： 10.1128/JVI.71.10.7960-7962.1997

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  15 in total

Review 1.  Use of adeno-associated virus as a general transduction vector for mammalian cells.

Authors:  N Muzyczka
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

2.  On the role of antigen in maintaining cytotoxic T-cell memory.

Authors:  T M Kündig; M F Bachmann; S Oehen; U W Hoffmann; J J Simard; C P Kalberer; H Pircher; P S Ohashi; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

3.  Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells.

Authors:  B Doe; M Selby; S Barnett; J Baenziger; C M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

4.  Nucleotide sequence and organization of the adeno-associated virus 2 genome.

Authors:  A Srivastava; E W Lusby; K I Berns
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

5.  Construction of a recombinant human parvovirus B19: adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus.

Authors:  C H Srivastava; R J Samulski; L Lu; S H Larsen; A Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 6.  MF59. Design and evaluation of a safe and potent adjuvant for human vaccines.

Authors:  G Ott; G L Barchfeld; D Chernoff; R Radhakrishnan; P van Hoogevest; G Van Nest
Journal:  Pharm Biotechnol       Date:  1995

7.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Adeno-associated virus general transduction vectors: analysis of proviral structures.

Authors:  S K McLaughlin; P Collis; P L Hermonat; N Muzyczka
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  Parvovirus B19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic progenitor cells.

Authors:  X S Wang; M C Yoder; S Z Zhou; A Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

10.  Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood.

Authors:  S Z Zhou; S Cooper; L Y Kang; L Ruggieri; S Heimfeld; A Srivastava; H E Broxmeyer
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307
View more
  37 in total

Review 1.  Adenoassociated virus vectors for genetic immunization.

Authors:  Selvarangan Ponnazhagan
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells.

Authors:  Y Zhang; N Chirmule; G p Gao; J Wilson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.

Authors:  Karen Nieto; Christiane Stahl-Hennig; Barbara Leuchs; Martin Müller; Lutz Gissmann; Jürgen A Kleinschmidt
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

4.  Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector.

Authors:  Romain Hardet; Benjamin Chevalier; Léa Dupaty; Yassine Naïmi; Gaëtan Riou; Laurent Drouot; Laetitia Jean; Anna Salvetti; Olivier Boyer; Sahil Adriouch
Journal:  Mol Ther       Date:  2015-08-12       Impact factor: 11.454

5.  Systemic protein delivery by muscle-gene transfer is limited by a local immune response.

Authors:  Lixin Wang; Eric Dobrzynski; Alexander Schlachterman; Ou Cao; Roland W Herzog
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

6.  Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Authors:  Philip R Johnson; Bruce C Schnepp; Mary J Connell; Daniela Rohne; Suzanne Robinson; Georgia R Krivulka; Carol I Lord; Rebekah Zinn; David C Montefiori; Norman L Letvin; K Reed Clark
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 7.  Challenges for gene therapy for muscular dystrophy.

Authors:  Jerry R Mendell; K Reed Clark
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

8.  Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Authors:  Shih-Wen Lin; Scott E Hensley; Nia Tatsis; Marcio O Lasaro; Hildegund C J Ertl
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

9.  Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.

Authors:  Jianping Lin; Yan Zhi; Lauren Mays; James M Wilson
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

10.  Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy.

Authors:  Victoria M Velazquez; David G Bowen; Christopher M Walker
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.